Duvelisib to be developed and commercialized for all oncology indications in China

On 25 September 2018 it was announced in a press release that duvelisib will be developed and commercialized by CSPC Pharmaceutical Group Limited in China for all oncology indications.

Duvelisib is the first oral dual inhibitor of phosphoinositide-3-kinase-delta (PI3K-δ) and PI3K-γ being developed by Verastem. The signed agreement with CSPC will mean that the Group will have exclusive development and commercialization rights of duvelisib holding the marketing authorization and product license. 

This follows the recent US FDA approval of duvelisib for the treatment of adult patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two prior lines of therapy. It has also received accelerated approval by the US FDA for the treatment of adult patients with R/R follicular lymphoma. 


Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF